MEDIA LIBRARY

CAP®AD – A VERSATILE PLATFORM FOR RCA-FREE, INDUSTRIAL SCALE ADENOVIRAL VECTOR PRODUCTION

White Paper by CEVEC authors Silke Wissing, Helmut Kewes and Nico Scheer

Bioprocess International Magazine, Multimedia Placement, October 2021

MANUFACTURING ADENOVIRAL VECTORS AT LARGE SCALE

How to select the best process and cell line to avoid RCA formation

Sponsored article by CEVEC authors Silke Wissing, Nicole Faust and Nico Scheer, Page 35

Genetic Engineering & Biotechnology News (GEN) – 40th Anniversary Edition, October 2021

HIGH TITER rAAV PRODUCTION IN BIOREACTOR USING ELEVECTA® STABLE PRODUCER CELL LINES

Scientific Poster, J. Coronel, A. Al-Dali, A. Patil, K. Srinivasan, T. Braß, K. Hein, S. Wissing

ESGCT 2021, October 2021

DEVELOPMENT OF A HEK293-BASED FULLY STABLE,
HELPER VIRUS-FREE ELEVECTA PRODUCTION SYSTEM FOR
rAAV

Scientific Poster, B Hudjetz, S Schmidt-Hertel, T Grabeck, K Srinivasan, A Al-Dali, J Coronel, N Strempel, N Faust, S Wissing

ESGCT 2021, October 2021

AAV MANUFACTURING WITH STABLE PRODUCER CELLS FOR INDUSTRIAL SCALE VECTOR PRODUCTION

Free Online Seminar, Dr. Ben Hudjetz, Senior Scientist Cell Line Development, CEVEC

Cell & Gene Therapy, Bio Insights – September 16, 2021

GENTHERAPIEN MIT AAV-VEKTOREN

CEVEC Pharmaceuticals: Hochleistungszelltechnologien für Biotherapeutika

Interview mit Dr. Nicole Faust, CEO, CEVEC

Plattform Life Science – September 2021

ELEVECTA® – HELPER VIRUS-FREE AAV PRODUCTION WITH STABLE CAP® AND HEK293 PRODUCER CELL

Free Online Seminar, Dr. Silke Wissing, Chief Scientific Officer

Cell & Gene Therapy Manufacturing & Commercialization
Digital Week – February 19, 2021

ELEVECTA® – THE FUTURE OF AAV GENE THERAPY VECTOR PRODUCTION

Pharmaceutical companies with gene therapies in their pipeline need to establish scalable production processes that can keep up with the increasing demand in terms of volume, quality and robustness, says CEVEC.

BPI Contributor – November 3, 2020 

HOW TO SOLVE THE PRODUCTION CHALLENGES OF AAVS FOR GENE THERAPY

CEVEC Pharmaceuticals has found a solution and developed a platform that can produce adeno-associated viral vectors (AAVs) as easily as if they were monoclonal antibodies.

Labiotech.eu – June 3, 2020

Read the interview with Nicole Faust, CEO of CEVEC

CEVEC PHARMACEUTICALS GMBH HAS LAUNCHED A NEW, SCALABLE PRODUCTION PLATFORM FOR AAV GENE THERAPY VECTORS.

At the time of Cevec Pharmaceuticals’s announcement, US researchers reported that AAV gene therapy might be the most promising way to bridge the therapeutic gap until a COVID-19 vaccine is available.

European Biotechnology – April 29, 2020

© CEVEC Pharmaceuticals GmbH 2021